136-LB: Efficacy and Safety of Sotagliflozin (SOTA) in Patients with Type 2 Diabetes (T2D) and Moderate Renal Impairment

Abstract

SOTA is a sodium-glucose linked cotransporter (SGLT)-1 in the GI tract and SGLT2 in the kidney. Compared to selective SGLT2 inhibitors, SOTA has the potential to retain glycemic-lowering efficacy in patients with renal insufficiency. In a 52-week, Phase 3 study, SOTA 200 and 400 mg QD, were evaluated in adults with T2D (HbA1C 7-11%) and Stage 3 CKD (eGFR ≥30-60 mL/min/1.73m2) to demonstrate statistical superiority vs. placebo (PBO) in reducing HbA1C at Week 26. Prespecified sequential testing of HbA1C reduction with SOTA 400 mg vs. PBO in the full CKD population was followed by Stage 3A and Stage 3B cohorts before testing SOTA 200 mg. ANCOVA models with retrieved dropouts and/or washout imputation methods were used for primary and prespecified secondary endpoints. In the full population (N=787), the least squares mean (LSM) difference between SOTA 400 mg and PBO for the change in HbA1C at Week 26 was −0.23% (p=0.002). In the CKD 3A (n=394) and CKD 3B cohorts (n=393), LSM differences for SOTA 400 mg vs. PBO were −0.31% (p=0.004) and −0.15% (p=0.158); respectively. SOTA 200 mg did not significantly reduce HbA1C in any cohort vs. PBO. In an exploratory analyses, PBO-corrected reductions in the urinary albumin-to-creatinine ratio were −38% (p<0.001) with SOTA 400 mg and −31% (p=0.001) with SOTA 200 mg. The expected “dip” in eGFR (3-4 mL/min/1.73 m2) with SOTA initiation was observed and trended back towards baseline. The rate of adverse events through 52 weeks was generally low. In the SOTA 400 mg, SOTA 200 mg, and PBO groups, genital mycotic infections (1.9%, 1.5%, and 0.8%), volume depletion (3.8%, 3.4%, and 1.5%), and diarrhea (8.5%, 6.7%, and 4.2%) were reported. Hypoglycemia ≤54 mg/dL was lower with SOTA 400 mg (5.4%) vs. PBO (10.8%). To conclude, statistically and clinically significant metabolic and renal effects of SOTA 400 mg were observed at 26 weeks in patients with T2D and Stage 3CKD. Long-term effects are being assessed in clinical outcomes trials. Disclosure D. Cherney: Research Support; Self; Boehringer Ingelheim-Lilly, Merck, Janssen, Sanofi, AstraZeneca and Novo-Nordisk. Other Relationship; Self; from Boehringer Ingelheim-Lilly, Merck, AstraZeneca, Sanofi, Mitsubishi-Tanabe, Abbvie, Janssen, Bayer, Prometic, BMS and Novo-Nordisk. E. Ferrannini: Consultant; Self; Boehringer Ingelheim International GmbH, Eli Lilly and Company, Oramed Pharmaceuticals. Research Support; Self; AstraZeneca, Janssen Pharmaceuticals, Inc. G.E. Umpierrez: None. A.L. Peters: Advisory Panel; Self; Abbott, Bigfoot Biomedical, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, MannKind Corporation, Medscape, Novo Nordisk Inc., Sanofi US. Consultant; Self; Livongo Health. Research Support; Self; Dexcom, Inc., vTv Therapeutics. Other Relationship; Self; Livongo Health, Mellitus Health, Omada Health, Stability Healthcare, Whole Biome Inc. J. Rosenstock: Research Support; Self; AstraZeneca, Bristol-Myers Squibb, Genentech, Inc., GlaxoSmithKline plc., Lexicon Pharmaceuticals, Inc., Oramed Pharmaceuticals, PegBio Co., Ltd., Pfizer Inc., REMD Biotherapeutics. Other Relationship; Self; Applied Therapeutics, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Intarcia Therapeutics, Janssen Pharmaceuticals, Inc., Novo Nordisk Inc., Sanofi. A.K. Carroll: Employee; Self; Lexicon Pharmaceuticals, Inc. Stock/Shareholder; Self; Lexicon Pharmaceuticals, Inc. S. Sawhney: None. P.L. Banks: Employee; Self; Lexicon Pharmaceuticals, Inc. W. Jiang: Employee; Self; Lexicon Pharmaceuticals, Inc. Stock/Shareholder; Self; Lexicon Pharmaceuticals, Inc. P. Lapuerta: Employee; Self; Lexicon Pharmaceuticals, Inc. Stock/Shareholder; Self; Lexicon Pharmaceuticals, Inc.